Biocryst Pharmaceuticals Inc Company Profile - Sep 08, 2011 by WrightReports

VIEWS: 1 PAGES: 11

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Biocryst Pharmaceuticals Inc
                                                                                         440 Wheelers Farms Road
                                                                                         Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:DCNN                                 Key Data

   BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs,       Ticker:
   optimizes and develops novel drugs that block enzymes involved in cancer, viral          BCRX
   infections and autoimmune diseases. BioCryst integrates the disciplines of biology,
   crystallography, medicinal chemistry and computer modeling to discover and develop       2010 Sales:
   small molecule pharmaceuticals through the process known as structure-based drug
                                                                                            62,381,336
   design. The Company's product candidate, forodesine HCl, is a transition-state
   analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). An oral
   formulation of the compound is in a Phase IIb trial for patients with Cutaneous T-cell   Major Industry:
   Lymphoma (CTCL). Additionally, forodesine HCl is being studied in a Phase II trial       Drugs, Cosmetics & Health
   with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its another drug         Care
   candidate, peramivir, is an inhibitor of influenza neuraminidase.
                       Stock Chart                                   Officers               Sub Industry:
                                                                     Chairman               Ethical Drug Manufacturers
                                                                Dr. Zola P. Horovitz
                                                                                            Country:
                                                         President & Chief Executive        United States
                                                              Jon P. Stonehouse
                                                                                            Currency:
                                                              Senior Vice President &       U.S. Dollars
                                                              Chief Financial Officer
                                                                Thomas R. Staab II
                                                                                            Fiscal Year Ends:
                                                                                            December

                                                                                            Employees
                                                                                            76

                                                                                            Exchanges:
                                                                                            NAS

                                                                                            Share Type:
                                                                                            Common
             Stock Price (9/2/2011): 2.91
              Recent stock performance
                                                                                            Market Capitalization:
                  1 Week        7.0%
                                 
								
To top